HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nicolas Kong Selected Research

Complementation Group A Molybdenum Cofactor Deficiency

1/2021Regulatory news: Nulibry (fosdenopterin) approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency type A: FDA approval summary.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nicolas Kong Research Topics

Disease

1Complementation Group A Molybdenum Cofactor Deficiency
01/2021
1Brain Edema (Cerebral Edema)
12/2014
1Hypotension (Low Blood Pressure)
12/2014
1Intracranial Hypertension
12/2014

Drug/Important Bio-Agent (IBA)

1nulibryIBA
01/2021
1Mannitol (Osmitrol)FDA LinkGeneric
12/2014

Therapy/Procedure

1Fluid Therapy (Oral Rehydration Therapy)
12/2014